TABLE 5.
Main findings from clinical and animal studies aimed to evaluate the therapeutic potential of CBD for the treatment of tobacco use disorder.
| CBD and nicotine | |||||
|---|---|---|---|---|---|
| Treatment | Doses, route of administration, and treatment duration | Study design/model | Subjects, samples, and gender | Main outcomes | References |
| Clinical studies | |||||
| CBD | 400 µg/inhalation solution erosol, inh. 7 days | Double-blind placebo-controlled trial | Smokers N = 24 (12 M and 12 F) | ↓ number of cigarettes smoked | Morgan et al. (2013) |
| CBD | 800 mg, p.o. Acute treatment | Double-blind placebo-controlled trial | Non-treatment seeking dependent smokers N = 30 (15 M and 15 F) | = Verbal or spatial working memory | Hindocha et al. (2018) |
| = withdrawal-induced impulsivity | |||||
| CBD | 800 mg, p.o. Acute treatment | Double-blind placebo-controlled trial | Non-treatment seeking dependent smokers N = 30 (16 M and 14 F) | ↓ attentional bias | Hindocha et al. (2018) |
| ↓ pleasantness of cigarette images | |||||
| = Tobacco craving | |||||
| = Withdrawal symptoms | |||||
| Animal studies | |||||
| CBD | 3, 10 and 30 mg/kg, s.c. Repeated treatment | Precipitated nicotine withdrawal | C57BL/6J mice (M) | ↑ NOR discrimination index during nicotine withdrawal | Saravia et al. (2019) |
CBD, cannabidiol; NOR, novel object recognition; M, male; F, female; inh., inhaled; p.o., per os (oral administration); s.c., subcutaneous injection; ↑, increase; ↓: decrease, = ; no effect.